Infant exposure to macrolide antibiotics is a risk factor for infantile hypertrophic pyloric stenosis (IHPS). The aim of the study was to establish whether perinatal exposure to non-macrolide antibiotics was a risk factor for IHPS.
A retrospective matched case-control study was performed using a database including all children born at Soroka University Medical Centre between 2006 and 2018. Cases and controls were compared using Student T-test and multiple logistic regression.
Of 189 461 children in the database, 63 infants were diagnosed with IHPS and underwent pyloromyotomy. There was no association between non-macrolide antibiotic exposure and IHPS. Maternal diabetes (DM) had an adjusted odds ratio for infants developing IHPS of 4.53 (p = 0.004).
The lack of association between exposure to non-macrolide antibiotics and IHPS suggests a quality unique to macrolides. An association between DM and IHPS may suggest elevated levels of IGF-1 have a role.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
The data that support the findings of this study are available from KAM but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of KAM.
Svenningsson A, Svensson T, Akre O, Nordenskjöld A. Maternal and pregnancy characteristics and risk of infantile hypertrophic pyloric stenosis. J Pediatr Surg. 2014;49:1226–31.
Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: Nationwide cohort study. BMJ 2014;348:g1908.
Krogh C, Biggar RJ, Fischer TK, Lindholm M, Wohlfahrt J, Melbye M. Bottle-feeding and the risk of pyloric stenosis. Pediatrics 2012;130:e943.
Krogh C, Gørtz S, Wohlfahrt J, Biggar RJ, Melbye M, Fischer TK. Pre-and perinatal risk factors for pyloric stenosis and their influence on the male predominance. Am J Epidemiol. 2012;176:24–31.
Murchison L, De Coppi P, Eaton S. Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: A systematic review and meta-analysis. Pediatr Surg Int. 2016;32:1147–52.
Leppälehto E, Pärtty A, Kalliomäki M, Löyttyniemi E, Isolauri E, Rautava S. Maternal intrapartum antibiotic administration and infantile colic: Is there a connection? Neonatology 2018;114:226–9.
Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. 2017;66:515–22.
Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139:380–4.
Azad MB, Konya T, Persaud RR, Guttman DS, Chari RS, Field CJ, et al. Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: A prospective cohort study. BJOG: Int J Obstet Gynaecol. 2016;123:983–93.
El-Gohary Y, Abdelhafeez A, Paton E, Gosain A, Murphy A. Pyloric stenosis: An enigma more than a century after the first successful treatment. Pediatr Surg Int. 2018;34:21–7.
Ericson J, Arnold C, Cheeseman J, Cho J, Kaneko S, Wilson E, et al. Use and safety of erythromycin and metoclopramide in hospitalized infants. J Pediatr Gastroenterol Nutr. 2015;61:334–9.
Pezzati M, Dani C, Biadaioli R, Gambi B, Lachina L, Rubaltelli F. Randomised controlled trial of the effect of cisapride on the pyloric muscle in preterm infants. Eur J Pediatr. 2001;160:572–5.
Riskin A, Itzchaki O, Bader D, Iofe A, Toropine A, Riskin-Mashiah S. Perinatal outcomes in infants of mothers with diabetes in pregnancy. Isr Med Assoc J. 2020;22:569–75.
Depla AL, De Wit L, Steenhuis TJ, Slieker MG, Voormolen DN, Scheffer PG, et al. Effect of maternal diabetes on fetal heart function on echocardiography: Systematic review and meta‐analysis. Ultrasound Obstet Gynecol. 2021;57:539–50.
Kuemmerle JF, Zhou H, Bowers JG. IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1 phase cell cycle proteins. Am J Physiol - Gastrointest Liver Physiol. 2004;286:412–9.
Jabłoński J, Gawrońska R, Gawłowska A, Kobos J, Andrzejewska E. Study of insulin-like growth factor-1 (IGF-1) and platelet-derived endothelial cell growth factor (PDEGF) expression in children with infantile hypertrophic pyloric stenosis. Med Sci Monit. 2006;12:CR27–CR30.
Fang X-S, Zhang M-S, Guo J-Y, Zheng J. Effects of insulin-like growth factor-1 on endoplasmic reticulum stress and autophagy in rat smooth muscle cells at different glucose concentrations in vitro. Mol Cell Biochem. 2019;451:11–20.
There are no competing financial interests in relation to the work described. The Soroka University Medical Centre (SUMC) research ethics committee approved the study. The study was performed in accordance with the Declaration of Helsinki.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cohen Elias, S., Yarza, S., Yerushalmi, B. et al. Infantile hypertrophic pyloric stenosis: maternal diabetes and perinatal exposure to non-macrolide antibiotics. J Perinatol (2023). https://doi.org/10.1038/s41372-023-01619-2